ID

34540

Beskrivning

Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02468284

Länk

https://clinicaltrials.gov/show/NCT02468284

Nyckelord

  1. 2019-01-19 2019-01-19 -
  2. 2019-05-22 2019-05-22 -
Rättsinnehavare

see on clinicaltrials.gov

Uppladdad den

19 januari 2019

DOI

För en begäran logga in.

Licens

Creative Commons BY-NC 3.0

Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Prostate Cancer NCT02468284

Eligibility Prostate Cancer NCT02468284

Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
has a histologically confirmed (gleason graded) adenocarcinoma of the prostate (all stages), for which endocrine therapy (except for neoadjuvant hormonal therapy) is indicated
Beskrivning

ID.1

Datatyp

boolean

has a prostate-specific antigen (psa) level ≥2.0 ng/ml at screening
Beskrivning

ID.2

Datatyp

boolean

has a screening serum testosterone level >150 ng/dl
Beskrivning

ID.3

Datatyp

boolean

has an eastern cooperative oncology group (ecog) score of ≤2
Beskrivning

ID.4

Datatyp

boolean

Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
has had previous or is currently under hormonal management of prostate cancer. however, hormonal therapy for a maximum duration of 6 months is accepted. this treatment should have been terminated at least 6 months prior to the screening visit
Beskrivning

ID.5

Datatyp

boolean

is currently treated with a 5-alpha reductase inhibitor
Beskrivning

ID.6

Datatyp

boolean

is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy
Beskrivning

ID.7

Datatyp

boolean

is in need of neoadjuvant hormonal therapy
Beskrivning

ID.8

Datatyp

boolean

has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy
Beskrivning

ID.9

Datatyp

boolean

Similar models

Eligibility Prostate Cancer NCT02468284

Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
has a histologically confirmed (gleason graded) adenocarcinoma of the prostate (all stages), for which endocrine therapy (except for neoadjuvant hormonal therapy) is indicated
boolean
ID.2
Item
has a prostate-specific antigen (psa) level ≥2.0 ng/ml at screening
boolean
ID.3
Item
has a screening serum testosterone level >150 ng/dl
boolean
ID.4
Item
has an eastern cooperative oncology group (ecog) score of ≤2
boolean
Item Group
C0680251 (UMLS CUI)
ID.5
Item
has had previous or is currently under hormonal management of prostate cancer. however, hormonal therapy for a maximum duration of 6 months is accepted. this treatment should have been terminated at least 6 months prior to the screening visit
boolean
ID.6
Item
is currently treated with a 5-alpha reductase inhibitor
boolean
ID.7
Item
is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy
boolean
ID.8
Item
is in need of neoadjuvant hormonal therapy
boolean
ID.9
Item
has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy
boolean

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial